Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 3
2012 1
2013 3
2014 5
2015 1
2016 1
2017 6
2018 9
2019 3
2020 4
2021 6
2022 8
2023 6
2024 8
2025 6
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Uses of complementary and alternative medicine in multiple sclerosis.
Namjooyan F, Ghanavati R, Majdinasab N, Jokari S, Janbozorgi M. Namjooyan F, et al. Among authors: majdinasab n. J Tradit Complement Med. 2014 Jul;4(3):145-52. doi: 10.4103/2225-4110.136543. J Tradit Complement Med. 2014. PMID: 25161918 Free PMC article. Review.
Primary progressive multiple sclerosis in Iran: A consensus recommendation for diagnosis and management.
Sahraian MA, Baghbanian SM, Langroodi HG, Abolfazli R, Alaie S, Asgari N, Ashtari F, Ayromlouh H, Moghadam NB, Foroughipour M, Majdinasab N, Mohammadianinejad SE, Nickseresht A, Nourian A, Shahmohammadi S, Shayegannejad V, Torabi HR. Sahraian MA, et al. Among authors: majdinasab n. Mult Scler Relat Disord. 2018 Nov;26:112-120. doi: 10.1016/j.msard.2018.09.013. Epub 2018 Sep 12. Mult Scler Relat Disord. 2018. PMID: 30245383 Review. No abstract available.
Characteristics of COVID-19 in patients with multiple sclerosis.
Ghadiri F, Sahraian MA, Shaygannejad V, Ashtari F, Ghalyanchi Langroodi H, Baghbanian SM, Mozhdehipanah H, Majdi-Nasab N, Hosseini S, Poursadeghfard M, Beladimoghadam N, Razazian N, Ayoubi S, Rezaeimanesh N, Eskandarieh S, Naser Moghadasi A. Ghadiri F, et al. Mult Scler Relat Disord. 2022 Jan;57:103437. doi: 10.1016/j.msard.2021.103437. Epub 2021 Nov 30. Mult Scler Relat Disord. 2022. PMID: 34896875 Free PMC article.
Effects of resveratrol supplementation on inflammatory markers, fatigue scale, fasting blood sugar and lipid profile in relapsing-remitting multiple sclerosis patients: a double-blind, randomized placebo-controlled trial.
Keramatzadeh S, Hosseini SA, Majdinasab N, Cheraghian B, Zilaee M. Keramatzadeh S, et al. Among authors: majdinasab n. Nutr Neurosci. 2025 Jul;28(7):854-862. doi: 10.1080/1028415X.2024.2425649. Epub 2024 Nov 20. Nutr Neurosci. 2025. PMID: 39565038 Clinical Trial.
Economic and Social Standing of Individuals in Iran Diagnosed with Multiple Sclerosis.
Ghadiri F, Sahraian MA, Ashtari F, Baghbanian SM, Majdi-Nasab N, Hatamian H, Faraji F, Bayati A, Sharifipour E, Jalali N, Mozhdehipanah H, Kamali H, Ayoubi S, Eskandarieh S, Naser Moghadasi A. Ghadiri F, et al. Arch Iran Med. 2023 Aug 1;26(8):413-418. doi: 10.34172/aim.2023.63. Arch Iran Med. 2023. PMID: 38301102 Free PMC article.
Longitudinal effects of dimethyl fumarate on patient-reported outcome measures in multiple sclerosis: treatment satisfaction, quality of life, depressive symptoms, sleep, and work productivity.
Abolfazli R, Sahraian MA, Shaygannejad V, Ashtari F, Shahmohammadi S, Poursadeghfard M, Baghbanian SM, Majdinasab N, Nahayati MA, Hosseini S, Azarfam JY, Navardi S, Torabi HR, Ayromlou H, Saeidi M, Talebi M, Nikseresht A, Niknam Z, Azimi A, Sedighi B, Ghiasian M, Ghalyanchi-Langroodi H, Pourakbar E, Heidari H, Kamali H, Mohammadianinejad E, Ghaffari M, Mosarrezaii A, Bayati A, Yaseri M, Shali A, Samadzadeh S. Abolfazli R, et al. Among authors: majdinasab n. J Clin Neurosci. 2026 Apr;146:111877. doi: 10.1016/j.jocn.2026.111877. Epub 2026 Jan 28. J Clin Neurosci. 2026. PMID: 41610777 Clinical Trial.
Late-onset multiple sclerosis in Iran: A report on demographic and disease characteristics.
Ghadiri F, Sahraian MA, Razazian N, Ashtari F, Poursadeghfard M, Nabavi SM, Navardi S, Baghbanian SM, Shaygannejad V, Harirchian MH, Beladimoghadam N, Majdinasab N, Hosseini S, Azimi A, Kamali H, Sharifipour E, Hosseini Nejad Mir N, Bayati A, Nahayati MA, Heidari H, Mozhdehipanah H, Ghalyanchi Langroodi H, Jalali N, Ayoubi S, Asadollahzadeh E, Ebadi Z, Eskandarieh S, Naser Moghadasi A. Ghadiri F, et al. Among authors: majdinasab n. Mult Scler Relat Disord. 2023 Feb;70:104493. doi: 10.1016/j.msard.2022.104493. Epub 2022 Dec 29. Mult Scler Relat Disord. 2023. PMID: 36638768
61 results